Metabolomic Technologies Inc. (MTI) is excited to announce the national expansion of its proprietary and innovative test, PolypDx™. This non-invasive, convenient urine test is a major breakthrough to detect adenomatous polyps and help prevent colon…
Metabolomic Technologies Inc. (MTI) announced the successful completion of a $3.2M USD Series A raise. The company's lead product, PolypDx™, is the world's first and only urine test for colorectal cancer screening. Developed in Canada, and patented…
Metabolomic Technologies was presented with the BioAlberta Company of the Year Award at the 20th Annual BioAlberta Awards Gala. This Award was presented to MTI for excellence and innovation with their flagship product, PolypDx™, and their strong…
DynaLIFE and Metabolomic Technologies Inc. (MTI) today unveiled a new state-of-the art clinical space in Edmonton enabling the assessment of an innovative new test for Albertans in the detection and prevention of colorectal cancer, the second most commonly…
MTI received notice from the USPTO that patent number 10,267,800 entitled, "Methods for the Assessment of Colorectal Cancer and Colorectal Polyps by Measurement of Metabolites in Urine" has been issued on April 23, 2019. The patent covers fundamental…
MTI's poster entitled “Urine Metabolomic Biomarker Panel for Colorectal Cancer” was recognized as a Presidential Poster at the ACG 2018 Annual Scientific Meeting in Philadelphia. Fewer than 5% of accepted abstracts each year receive this distinction…
Metabolomic Technologies Inc. today announced the launch of a $1.4 million project that will evaluate a new colorectal cancer screening strategy using PolypDx™, the first and only urine test for the detection and prevention of colorectal cancer. The…
MTI is excited to be attending the 2018 American College of Gastroenterology Conference in Philadelphia, PA. Team members will be on site ready to discuss the first and only urine test for detection and prevention of colorectal cancer, PolypDx™.…
Metabolomic Technologies Inc. is selected as one of 20 outstanding science based start-ups from leading international academic institutions and international venture capitalists in the Falling Walls Venture competition held in Berlin, Germany. As…
Metabolomic Technologies Inc. is the 2017 recipient of the Outstanding Leadership in Technology Award from the ASTech Foundation. The ASTech Foundation award recognizes outstanding innovation in science and technology in Alberta....
Metabolomic Technologies Inc. has been granted a patent for its PolypDx™ technology by the European Patent Office. PolypDx™ received patent approval in Japan in September, 2015, and in Australia in February, 2017. Patents are also pending in the…
Metabolomic Technologies Inc. announces that it has appointed David Chang as Chief Executive Officer as of May 1st, 2017. Dr. Chang replaces Reg Joseph as CEO. He brings to the position 15 years experience managing SMEs and commercializing research projects.…
On June 6, 2017 MTI was presented with the 2017 ATB Catalyst Export Award. The award recognizes MTI's engagement in international business and export, while achieving excellence through sustainable growth and innovation....
MTI's Senior Scientist, Lu Deng, featured in Mitacs' Showcase of 150 Canadian Innovators for Canada's 150th Birthday...
MTI is excited to be attending the 2017 Digestive Disease Week Conference, May, 2017 in Chicago, IL. Team members will be on site ready to discuss our non-invasive urine-based diagnostic test for detection of adenomatous polyps, PolypDx™. Come check…
MTI is pleased to announce the launch of a new product website for our flagship product, PolypDx™. This website will provide important education and information on PolypDx™ for both patients and healthcare professionals, as we expand coverage of PolypDx™…
From March 20 to 23, 2017, MTI's Dr. David Chang travelled to Beijing and Tianjin, China, as part of a delegation of medical device companies from Canada. PolypDx™ was featured as a leading potential diagnostic for the Chinese market. ...
In early February, 2017, Metabolomic Technologies Inc. was granted a patent for its PolypDx™ technology by the Australian Patent Office. PolypDx™ received patent approval in Japan in September, 2015. Patents are also pending in the US, Canada, and…
MTI has signed a multi-year, non-exclusive licensing and distribution agreement with U.S. based Evolution Laboratories for its flagship product, PolypDx™, a urine-based diagnostic test for detection of adenomatous polyps, the precursor to colorectal…
Dr. Lu Deng was selected for this national award for her work, which successfully transferred MTI's flagship test, PolypDx™, from expensive, highly specialized equipment to a mass-spectrometer - the technology used in medical laboratories across…